Artiva Biotherapeutics (NASDAQ:ARTV) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• Artiva Biotherapeutics has received a "sell (e+)" rating from Weiss Ratings, competing against a recent upgrade to "buy" from HC Wainwright, which set a target price of $12.00.
• The stock is currently priced at $3.00, with a 1-year high of $16.87 and a low of $1.47, indicating significant volatility in its market performance.
• CEO Fred Aslan sold 25,500 shares at $2.73, reflecting a 6.19% decrease in his ownership, while institutional investors have recently increased their stakes in the company.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright upgraded Artiva Biotherapeutics to a "buy" rating and set a $12.00 target price on the stock in a report on Wednesday, June 11th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV traded up $0.10 during mid-day trading on Wednesday, reaching $3.00. The company had a trading volume of 25,200 shares, compared to its average volume of 201,777. The company has a 50-day moving average price of $2.85 and a two-hundred day moving average price of $2.44. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $16.87.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). As a group, sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Fred Aslan sold 25,500 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $2.73, for a total transaction of $69,615.00. Following the completion of the sale, the chief executive officer owned 386,693 shares in the company, valued at approximately $1,055,671.89. This represents a 6.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 21.40% of the company's stock.

Institutional Trading of Artiva Biotherapeutics

Large investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $53,000. Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $67,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $58,000. Marshall Wace LLP bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $48,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.